JP2017513503A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513503A5 JP2017513503A5 JP2016564068A JP2016564068A JP2017513503A5 JP 2017513503 A5 JP2017513503 A5 JP 2017513503A5 JP 2016564068 A JP2016564068 A JP 2016564068A JP 2016564068 A JP2016564068 A JP 2016564068A JP 2017513503 A5 JP2017513503 A5 JP 2017513503A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor agonist
- trail receptor
- agonist protein
- tumor
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000018102 proteins Nutrition 0.000 claims 16
- 102000004169 proteins and genes Human genes 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 229940123369 TRAIL receptor agonist Drugs 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 238000000034 method Methods 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 2
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000004481 post-translational protein modification Effects 0.000 claims 2
- 229940043131 pyroglutamate Drugs 0.000 claims 2
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims 1
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983152P | 2014-04-23 | 2014-04-23 | |
| US61/983,152 | 2014-04-23 | ||
| PCT/US2015/027270 WO2015164588A1 (en) | 2014-04-23 | 2015-04-23 | Single-chain trail-receptor agonist proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019082671A Division JP6714751B2 (ja) | 2014-04-23 | 2019-04-24 | 単鎖ｔｒａｉｌ受容体アゴニストタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513503A JP2017513503A (ja) | 2017-06-01 |
| JP2017513503A5 true JP2017513503A5 (cg-RX-API-DMAC7.html) | 2018-05-31 |
| JP6523331B2 JP6523331B2 (ja) | 2019-05-29 |
Family
ID=53055121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564068A Expired - Fee Related JP6523331B2 (ja) | 2014-04-23 | 2015-04-23 | 単鎖ｔｒａｉｌ受容体アゴニストタンパク質 |
| JP2019082671A Expired - Fee Related JP6714751B2 (ja) | 2014-04-23 | 2019-04-24 | 単鎖ｔｒａｉｌ受容体アゴニストタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019082671A Expired - Fee Related JP6714751B2 (ja) | 2014-04-23 | 2019-04-24 | 単鎖ｔｒａｉｌ受容体アゴニストタンパク質 |
Country Status (38)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017023646A2 (pt) | 2015-05-04 | 2018-07-17 | Apogenix Ag | proteínas agonistas de receptor de cd40 de cadeia simples |
| CA3002602C (en) | 2015-10-23 | 2021-11-02 | Apogenix Ag | Single-chain cd27-receptor agonist proteins |
| CA3002587A1 (en) | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain light receptor agonist proteins |
| CN108473549A (zh) * | 2015-10-23 | 2018-08-31 | 阿珀吉科吉尼科斯股份公司 | 单链gitr受体激动剂蛋白 |
| WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| JP7091248B2 (ja) | 2016-03-01 | 2022-06-27 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ | 低減されたｌ－グルタミナーゼ活性および増強された安定性を有するｌ－アスパラギナーゼ変異体および融合タンパク質 |
| KR20180127407A (ko) * | 2016-03-16 | 2018-11-28 | 메리맥 파마슈티컬즈, 인크. | 암 요법용 조작된 trail |
| US10501744B2 (en) | 2016-05-04 | 2019-12-10 | Indiana University Research And Technology Corporation | Presentation of bioactive proteins |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| AU2017283487A1 (en) * | 2016-06-13 | 2018-11-22 | Merrimack Pharmaceuticals, Inc. | Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| WO2019032952A1 (en) * | 2017-08-11 | 2019-02-14 | The Board Of Trustees Of The University Of Illinois | TRUNCATED VARIANTS OF INDIA PIG ASPARAGINASE AND METHODS OF USE |
| TW202002952A (zh) | 2018-03-15 | 2020-01-16 | 美商艾伯維有限公司 | 用於治療胰臟癌之abbv-621與抗癌劑之組合 |
| WO2019178438A1 (en) | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 in combination with anti-cancer agents for the treatment of cancer |
| CN115836084A (zh) | 2020-05-15 | 2023-03-21 | 阿珀吉尼科斯股份公司 | 多特异性免疫调节剂 |
| CA3217894A1 (en) | 2021-05-28 | 2022-12-01 | Gernot Stuhler | Recombinant proteinaceous binding molecules |
| WO2023088876A1 (en) | 2021-11-16 | 2023-05-25 | Apogenix Ag | Multi-specific immune modulators |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR025984A1 (es) | 1999-10-07 | 2002-12-26 | Maxygen Aps | Polipeptidos oligomericos de cadena simple |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| CA2314199A1 (en) | 2000-07-21 | 2002-01-21 | Robert Simoneau | C-chip |
| ATE406384T1 (de) | 2000-12-07 | 2008-09-15 | Lilly Co Eli | Glp-1 fusion proteine |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| AU2003234274A1 (en) | 2002-04-26 | 2003-11-10 | California Institute Of Technology | D1-1 nucleic acids, polypeptides and related methods |
| DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
| US8388962B2 (en) | 2005-04-15 | 2013-03-05 | Rappaport Family Institute For Research In The Medical Sciences | Molecules and methods of using same for treating MCP-1/CCR2 associated diseases |
| WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| EP1894940A1 (en) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
| ES2560871T3 (es) | 2007-07-10 | 2016-02-23 | Apogenix Gmbh | Proteínas de fusión de colectina de la superfamilia de TNF |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| JP5674155B2 (ja) * | 2008-07-21 | 2015-02-25 | アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ | Ｔｎｆｓｆ一本鎖分子 |
| CA2737280A1 (en) * | 2008-09-22 | 2010-03-25 | Amgen Inc. | Method of treatment |
| EP2379585A2 (en) * | 2008-10-10 | 2011-10-26 | Anaphore, Inc. | Polypeptides that bind trail-ri and trail-r2 |
| EP2829550B1 (en) | 2009-01-09 | 2016-11-16 | Apogenix AG | Fusion proteins forming trimers |
| JP2012515556A (ja) * | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法 |
| TW201130511A (en) | 2009-12-22 | 2011-09-16 | Novartis Ag | Soluble proteins for use as therapeutics |
| AU2011240620A1 (en) | 2010-04-13 | 2012-10-18 | Medimmune, Llc | Fibronectin type III domain-based multimeric scaffolds |
| US9717803B2 (en) * | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
| CA2878992C (en) | 2012-07-18 | 2020-09-22 | Apogenix Gmbh | Composition comprising a mixture of cd95-fc isoforms |
-
2012
- 2012-11-06 NO NO12790406A patent/NO2776305T3/no unknown
-
2015
- 2015-04-23 BR BR112016024515-6A patent/BR112016024515B1/pt not_active IP Right Cessation
- 2015-04-23 TW TW109106778A patent/TWI747178B/zh not_active IP Right Cessation
- 2015-04-23 PT PT157210899T patent/PT3134430T/pt unknown
- 2015-04-23 RS RS20180450A patent/RS57153B1/sr unknown
- 2015-04-23 MA MA045069A patent/MA45069A/fr unknown
- 2015-04-23 SG SG11201608767XA patent/SG11201608767XA/en unknown
- 2015-04-23 SI SI201530223T patent/SI3134430T1/en unknown
- 2015-04-23 EP EP15721089.9A patent/EP3134430B1/en active Active
- 2015-04-23 CN CN201580031858.7A patent/CN106459221B/zh not_active Expired - Fee Related
- 2015-04-23 EP EP18155146.6A patent/EP3366699A1/en not_active Withdrawn
- 2015-04-23 US US14/694,358 patent/US9908927B2/en active Active
- 2015-04-23 CA CA3184067A patent/CA3184067A1/en active Pending
- 2015-04-23 PE PE2016002016A patent/PE20170299A1/es unknown
- 2015-04-23 MA MA039770A patent/MA39770A/fr unknown
- 2015-04-23 PH PH1/2020/500377A patent/PH12020500377A1/en unknown
- 2015-04-23 CA CA2946402A patent/CA2946402C/en active Active
- 2015-04-23 KR KR1020167032819A patent/KR102079919B1/ko not_active Expired - Fee Related
- 2015-04-23 HR HRP20180950TT patent/HRP20180950T1/hr unknown
- 2015-04-23 PL PL15721089T patent/PL3134430T3/pl unknown
- 2015-04-23 CN CN202010767219.XA patent/CN111718424A/zh active Pending
- 2015-04-23 AR ARP150101224A patent/AR100168A1/es active IP Right Grant
- 2015-04-23 HU HUE15721089A patent/HUE038914T2/hu unknown
- 2015-04-23 AU AU2015249649A patent/AU2015249649B2/en not_active Ceased
- 2015-04-23 UY UY0001036095A patent/UY36095A/es active IP Right Grant
- 2015-04-23 RU RU2016145608A patent/RU2699285C2/ru active
- 2015-04-23 LT LTEP15721089.9T patent/LT3134430T/lt unknown
- 2015-04-23 SG SG10202111785VA patent/SG10202111785VA/en unknown
- 2015-04-23 JP JP2016564068A patent/JP6523331B2/ja not_active Expired - Fee Related
- 2015-04-23 UA UAA201611802A patent/UA118286C2/uk unknown
- 2015-04-23 KR KR1020197035100A patent/KR20190135546A/ko not_active Ceased
- 2015-04-23 TR TR2018/06912T patent/TR201806912T4/tr unknown
- 2015-04-23 SG SG10201806465TA patent/SG10201806465TA/en unknown
- 2015-04-23 TW TW104113087A patent/TWI683825B/zh not_active IP Right Cessation
- 2015-04-23 MY MYPI2016703814A patent/MY181986A/en unknown
- 2015-04-23 SM SM20180286T patent/SMT201800286T1/it unknown
- 2015-04-23 CR CR20160516A patent/CR20160516A/es unknown
- 2015-04-23 WO PCT/US2015/027270 patent/WO2015164588A1/en not_active Ceased
- 2015-04-23 ES ES15721089.9T patent/ES2672368T3/es active Active
- 2015-04-23 MX MX2016013858A patent/MX2016013858A/es active IP Right Grant
- 2015-04-23 DK DK15721089.9T patent/DK3134430T3/en active
-
2016
- 2016-10-07 IL IL248244A patent/IL248244B/en active IP Right Grant
- 2016-10-19 PH PH12016502079A patent/PH12016502079B1/en unknown
- 2016-10-19 DO DO2016000284A patent/DOP2016000284A/es unknown
- 2016-10-21 MX MX2019013587A patent/MX2019013587A/es unknown
- 2016-10-21 CL CL2016002683A patent/CL2016002683A1/es unknown
- 2016-11-23 EC ECIEPI201689579A patent/ECSP16089579A/es unknown
-
2018
- 2018-02-02 US US15/887,509 patent/US20180222962A1/en not_active Abandoned
- 2018-05-25 CY CY20181100568T patent/CY1120281T1/el unknown
- 2018-11-30 AU AU2018271369A patent/AU2018271369B2/en not_active Ceased
-
2019
- 2019-04-24 JP JP2019082671A patent/JP6714751B2/ja not_active Expired - Fee Related
-
2020
- 2020-02-11 IL IL272612A patent/IL272612A/en unknown
- 2020-03-30 AU AU2020202247A patent/AU2020202247A1/en not_active Abandoned
- 2020-08-14 US US16/993,569 patent/US20210040178A1/en not_active Abandoned
-
2023
- 2023-07-14 US US18/352,769 patent/US20240174731A1/en not_active Abandoned
-
2024
- 2024-09-23 US US18/892,964 patent/US20250145688A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513503A5 (cg-RX-API-DMAC7.html) | ||
| RU2016145608A (ru) | Одноцепочечные белки агонисты trail-рецептора | |
| JP2017528419A5 (cg-RX-API-DMAC7.html) | ||
| BR112015020315A2 (pt) | conjugação de anticorpo-fármaco sítio-específica por glicoengenharia | |
| MX2021000801A (es) | Agonistas de il2. | |
| IL288541B (en) | Vaccine against rsv | |
| EA202190906A1 (ru) | Рекомбинантное получение препаратов пептидов коллагена и их применение | |
| FI3549949T3 (fi) | Clostridium difficile -mutanttitoksiiniin liittyviä koostumuksia ja menetelmiä | |
| HRP20231496T1 (hr) | Cistein proteaza | |
| JP2019510739A5 (cg-RX-API-DMAC7.html) | ||
| AR105616A1 (es) | Proteínas de fusión | |
| RU2015136440A (ru) | Композиции и способы применения для лечения метаболических расстройств | |
| WO2015061416A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
| MX2020010806A (es) | Peptidos anti-inflamatorios y usos de los mismos. | |
| JP2015513318A5 (cg-RX-API-DMAC7.html) | ||
| JP2016506727A5 (cg-RX-API-DMAC7.html) | ||
| FI3712264T3 (fi) | Kystationiini-beta-syntaasientsyymi homokystinurian hoitoon | |
| FI3518982T3 (fi) | Säädellysti vapautuvia PTH-yhdisteitä | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| AR099068A1 (es) | Anticuerpo anti-netrina-1 | |
| JP2017524380A5 (ja) | 腫瘍血管遮断剤であるポリペプチド、遺伝子、発現ベクター、腫瘍血管遮断剤の組成物、及び腫瘍血管遮断剤であるポリペプチドの調製方法 | |
| US9388213B2 (en) | Polycomb repressive complex 2 (PRC2) inhibitors and uses thereof | |
| RU2015110114A (ru) | Ангиотензин в лечении состояний головного мозга | |
| MY206268A (en) | Modified s1 subunit of the coronavirus spike protein | |
| BR112018073669A2 (pt) | proteína de fusão, composição de uma primeira proteína e uma segunda proteína, complexo de uma primeira proteína e uma segunda proteína, polinucleotídeos que codificam uma proteína de fusão, vetor contendo o polinucleotídeo, célula hospedeira contendo o polinucleotídeo, uso de uma proteína de fusão, composição farmacêutica, e composição farmacêutica para uso |